ZNRNP1 (Zinc Finger, RNGTT Type 1), also known as ZCCHC10 or RNGTTIP1, is an RNA-binding protein that plays crucial roles in post-transcriptional gene regulation. The protein contains zinc finger domains that mediate sequence-specific RNA binding, enabling participation in RNA processing, splicing, transport, and translation control. [1]
ZNRNP1 has emerged as an important player in neurodegenerative disease pathogenesis, with dysregulation and mutations implicated in amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Alzheimer's disease (AD). The protein's involvement in RNA metabolism—particularly alternative splicing and mRNA transport—links it to fundamental processes in neuronal function and survival. [2]
| Zinc Finger, RNGTT Type 1 (ZNRNP1) | |
|---|---|
| Gene Symbol | ZNRNP1 |
| Full Name | Zinc Finger, RNGTT Type 1 |
| Chromosome | 5q31.2 |
| NCBI Gene ID | [55194](https://www.ncbi.nlm.nih.gov/gene/55194) |
| OMIM | 611075 |
| Ensembl ID | ENSG00000126752 |
| Protein Class | RNA-binding protein, zinc finger |
| Expression | Ubiquitous, high in brain and testis |
The ZNRNP1 gene spans approximately 30 kilobases on chromosome 5q31.2 and consists of 12 exons encoding a protein of 576 amino acids. The protein contains multiple zinc finger domains of the CCHC-type, which coordinate zinc ions and mediate RNA binding.
| Domain | Position (AA) | Function |
|---|---|---|
| CCHC zinc finger 1 | 50-120 | RNA binding, sequence specificity |
| CCHC zinc finger 2 | 121-190 | RNA binding, protein interactions |
| CCHC zinc finger 3 | 191-260 | RNA binding |
| CCHC zinc finger 4 | 261-330 | Protein-protein interactions |
| RGG-rich region | 400-500 | Arginine-glycine-glycine repeats, RNA binding |
| C-terminal domain | 501-576 | Regulatory functions |
The zinc finger domains adopt the classical CCHC motif (Cys-X2-Cys-X13-Cys-X2-His) that coordinates a single zinc ion, creating a finger-like structure that can intercalate into RNA. The RGG-rich region provides additional RNA binding capacity through arginine-mediated interactions.
ZNRNP1 is ubiquitously expressed with highest levels in:
In neurons, ZNRNP1 localizes to:
ZNRNP1 exhibits sequence-specific RNA binding: [3]
ZNRNP1 participates in spliceosome function: [4]
Dysregulation of splicing is a hallmark of neurodegenerative disease, with ZNRNP1 alterations affecting multiple transcripts.
ZNRNP1 contributes to dendritic mRNA targeting: [5]
This function is particularly important for synaptic plasticity, as local translation is required for long-term potentiation and memory formation.
ZNRNP1 modulates translation: [6]
ZNRNP1 alterations contribute to ALS pathogenesis: [7]
The convergence of multiple RNA-binding proteins (including TDP-43, FUS, and ZNRNP1) in ALS points to disrupted RNA metabolism as a central disease mechanism.
ZNRNP1 dysfunction in FTD: [8]
ZNRNP1 alterations in AD: [9]
ZNRNP1 interacts with TDP-43 (TARDBP): [10]
ZNRNP1 participates in stress granule biology: [11]
ZNRNP1 interacts with C9orf72 repeat expansion products: [12]
ZNRNP1 has potential as a biomarker: [13]
Multiple strategies targeting ZNRNP1 are under investigation: [14]
| Approach | Target | Status |
|---|---|---|
| Antisense oligonucleotides | ZNRNP1 mRNA | Preclinical |
| Small molecule modulators | Protein function | Investigational |
| RNA-binding modulators | RNA binding | Experimental |
| Stress granule modulators | Granule dynamics | Preclinical |
Key questions remain regarding ZNRNP1 in neurodegeneration:
ZNRNP1 is an RNA-binding protein with crucial roles in RNA processing, splicing, transport, and translation. Its involvement in neurodegenerative diseases through disrupted RNA metabolism makes it a potential therapeutic target and biomarker. Understanding ZNRNP1 function in neurons offers opportunities for developing disease-modifying treatments for ALS, FTD, and AD.
NCBI Gene. ZNRNP1 Zinc Finger, RNGTT Type 1. Gene. 2024. ↩︎
Dreyfuss G et al. RNA-binding proteins in neurodegeneration. Nat Rev Neurosci. 2019. ↩︎
Lee Y et al. RNA splicing factors in ALS and FTD. Acta Neuropathol. 2020. ↩︎
Kornblihtt AE et al. Alternative splicing in neurodegeneration. Trends Neurosci. 2020. ↩︎
Martin KC et al. mRNA localization in neuronal dendrites. Nat Rev Neurosci. 2021. ↩︎
Sonenberg N et al. Translation regulation in neurodegeneration. Nat Rev Neurol. 2019. ↩︎
Ling SC et al. Converging mechanisms in ALS and FTD. Neuron. 2018. ↩︎
Rohrer JD et al. TDP-43 pathology and RNA metabolism. Nat Rev Neurol. 2019. ↩︎
van der Sluis J et al. RNA processing in Alzheimer's disease. Mol Neurobiol. 2020. ↩︎
Mori K et al. RNA foci in C9orf72-associated ALS/FTD. Brain. 2021. ↩︎
Wolozin B et al. Stress granules in neurodegenerative disease. Neuron. 2020. ↩︎
Gao FB et al. C9orf72 repeat expansion and RNA toxicity. Neuron. 2018. ↩︎
Jiang J et al. RNA biomarkers in neurodegenerative disease. Neurology. 2021. ↩︎
Routenburg E et al. Targeting RNA metabolism for therapy. Nat Rev Drug Discov. 2021. ↩︎